Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Immunophotonics secures $10 million in Series C financing, appointing Robert H. Arch, Ph.D., as CEO to support the advancement of IP-001 clinical development.

PRIVATESep 01, 2026•2 days ago

Amount Raised

$10 Million

Round Type

Series C

St. LouisHealthcare

Description

Immunophotonics has closed $10 million in Series C financing to support the ongoing clinical development of its lead drug candidate, IP-001. This funding will enable advancement of clinical Phase 2 programs and key corporate objectives. The company appointed Robert H. Arch, Ph.D., as President and CEO, effective September 1, 2026

Company Information

Company

Immunophotonics

Location

4340 Duncan Ave.

St. Louis, Missouri, United States

About

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Don't miss Immunophotonics's next move

Get an email the moment Immunophotonics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
1 contact
Verified contactsLu A., Executive Officer, Director, Promoter hidden hidden
Predictive Intelligence
Strategic

ML-powered predictions for Immunophotonics's next move

See what Strategic adds

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Immunophotonics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.